India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation
Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.
Fiscal Year: January - December
Eli Lilly and Company (LLY), listed on the NYSE, has a market capitalization of $837.17B. As of Apr 03, 2026, the stock is trading at $935.58 per share@else an unavailable price , offering investors a clear view of its current market value. Eli Lilly and Company is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 40.77, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Eli Lilly and Company also offers a dividend yield of 0.74%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Eli Lilly and Company (LLY) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Eli Lilly and Company is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Eli Lilly and Company, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Eli Lilly and Company is 93.31, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Eli Lilly and Company (LLY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Eli Lilly and Company (LLY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Eli Lilly and Company (LLY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Eli Lilly and Company. To access the full SS Score, consider upgrading your subscription.
Eli Lilly and Company is a significant player in the industry sector, with a market capitalization of $837.17B and a competitive P/E ratio of 40.77. Investors should compare these metrics with industry peers to gauge whether Eli Lilly and Company is outperforming or underperforming within its sector.
Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.
A new GLP-1 pill is about to hit the market. On Wednesday, Eli Lilly and Co. announced that its new GLP-1 pill, Foundayo, was approved by the Food and Drug Administration (FDA) for use in adults with ...
There's always opportunity in markets if you know where to look, says Tiffany McGhee. She offers insight into how her firm positions portfolios in times of profound volatility, including now as the U....
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC ...
Eli Lilly And Company (NYSE: LLY) shares are down approximately 1% Thursday despite FDA approval of its oral weight-loss drug Foundayo on Wednesday, as geopolitical tensions weigh on broader markets.
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously publi...
Eli Lilly's newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts betting it will quickly narrow Novo Nordisk's head start in the oral market.
Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More ...
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker's efforts to expan...
The U.S. Food and Drug Administration has approved Eli Lilly's weight-loss pill, bringing another oral alternatives to a market dominated by injectables and intensifying competition with Novo Nordisk...
Eli Lilly opposes the White House's push to codify 'Most Favored Nations' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...
The Food and Drug Administration has approved Foundayo, Eli Lilly's new GLP-1 pill to treat weight loss—the second oral weight loss drug to hit the market after Novo Nordisk's Wegovy was greenlit last...
The Food and Drug Administration on Wednesday approved Foundayo, an oral GLP-1 medication that is expected to produce tens of billions of dollars at its peak. Lilly's stock LLY+4.12% jumped 5% after t...
Eli Lilly Chair & CEO Dave Ricks tells CNBC's Angelica Peebles that with the approval of the company's GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the glo...
Eli Lilly's Foundayo will be available to patients through the drugmaker's online pharmacy.
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight-loss pill, making it the second to market after Novo Nordisk's oral Wegovy, as the companies fight to capture more...
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
CNBC's Jim Cramer delivers his daily Mad Dash.
Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect ® with...
The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenienc...
Some people believe the market is random. They think it isn't possible to time the market.
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug ...
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 12.26B | 226.03% | Est @226.0% |
| 2026 | 20.76B | 69.33% | Analyst x6 |
| 2027 | 28.26B | 36.13% | Analyst x6 |
| 2028 | 34.48B | 22.01% | Analyst x6 |
| 2029 | 41.31B | 19.82% | Analyst x5 |
| 2030 | 47.38B | 14.70% | Analyst x5 |
| 2031 | 50.88B | 7.39% | Est @7.4% |
| 2032 | 53.90B | 5.94% | Est @5.9% |
| 2033 | 56.56B | 4.92% | Est @4.9% |
| 2034 | 58.78B | 3.93% | Est @3.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 792.00M | 1.00 | 792.00M |
| 2024A | 3.76B | 1.00 | 3.76B |
| 2025E | 12.26B | 1.08 | 11.37B |
| 2026E | 20.76B | 1.16 | 17.85B |
| 2027E | 28.26B | 1.25 | 22.53B |
| 2028E | 34.48B | 1.35 | 25.49B |
| 2029E | 41.31B | 1.46 | 28.32B |
| 2030E | 47.38B | 1.57 | 30.12B |
| 2031E | 50.88B | 1.70 | 29.99B |
| 2032E | 53.90B | 1.83 | 29.46B |
| 2033E | 56.56B | 1.97 | 28.66B |
| 2034E | 58.78B | 2.13 | 27.63B |
| Terminal | 1.13T | 2.13 | 529.94B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.